Drug Trial Radar · NCT07444567
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Jul 24, 2026
Primary completion
Dec 27, 2029
Study completion Dec 27, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.
Conditions
- Asthma
- Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Hypereosinophilic Syndrome (HES)
Interventions
BenralizumabDrug
Accessorized Pre-Filled Syringe (Solution for injection).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumabTime frame: From baseline until 8 weeks after the last dose of benralizumab
Locations
46 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Aurora, Colorado · Not yet recruiting
Research Site
Bethesda, Maryland · Not yet recruiting
Research Site
Ann Arbor, Michigan · Not yet recruiting
Research Site
Northfield, New Jersey · Not yet recruiting
Research Site
The Bronx, New York · Not yet recruiting
Research Site
Durham, North Carolina · Not yet recruiting
Research Site
Cleveland, Ohio · Recruiting
Research Site
Salt Lake City, Utah · Not yet recruiting
Research Site
Buenos Aires, Argentina · Recruiting
Research Site
Florida, Argentina · Recruiting
Research Site
Lobos, Argentina · Not yet recruiting
Research Site
Mar del Plata, Argentina · Recruiting
Research Site
Mendoza, Argentina · Recruiting
Research Site
Mendoza, Argentina · Recruiting
Research Site
Rosario, Argentina · Recruiting
Research Site
San Juan Bautista, Argentina · Not yet recruiting
Research Site
Innsbruck, Austria · Not yet recruiting
Research Site
Brussels, Belgium · Recruiting
Research Site
Edegem, Belgium · Not yet recruiting
Research Site
Calgary, Alberta, Canada · Not yet recruiting
Research Site
Hamilton, Ontario, Canada · Recruiting
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
Toronto, Ontario, Canada · Not yet recruiting
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
Bron, France · Not yet recruiting
Research Site
Marseille, France · Recruiting
Research Site
Montpellier, France · Recruiting
Research Site
Nantes, France · Recruiting
Research Site
Paris, France · Recruiting
Research Site
Paris, France · Recruiting
Research Site
Pessac, France · Recruiting
Research Site
Suresnes, France · Recruiting
Research Site
Ahmedabad, India · Withdrawn
Research Site
Ajmer, India · Not yet recruiting
Research Site
Haifa, Israel · Recruiting
Research Site
Holon, Israel · Recruiting
Research Site
Petah Tikva, Israel · Not yet recruiting
Research Site
Roma, Italy · Withdrawn
Research Site
Rotterdam, Netherlands · Not yet recruiting
Research Site
Chęciny, Poland · Not yet recruiting
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.